说明：博格一共有3个主要投资账户。 主要账户分别是：场内etf账户、场外某基金账户、场外投顾组合账户。 因投顾组合账户净值更新较晚，所以工作日仅统计场内账户和场外某基金账户。每周周六周报统计3个主要账户收益。 今天码字较多，下文有密集干货和文末礼品，需要大家多一点耐心阅读时间~ 截至2025年最后一个交易日收盘后： 合计持仓超过1000万（还有一些散装账户），2025年合计盈利184万，收益率为33.89%。 相比2025盈利最高时候的230万元，浮盈回撤了46万元。 一、场内ETF账户 | ( | 股票证券 | | | じく | | 公易 郑*勇 3275***4918 | C | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025年收益额 | | | ⇌ 看收益率 | 买入 | 委员 | 撤单 持仓 | 查询 | | +438.046.77 | | | | 市值 = | 持仓/可用 ( 现价/成本价(2 | | 总盈亏; | | 年 月 | | ▲ 2025年 | | 港股创新药 ... | 270000 | 1.194 | +133,125. ...

Market Performance - The Shanghai Composite Index closed flat, marking a 10-day consecutive rise, while the Shenzhen Component Index increased by 0.49% and the ChiNext Index rose by 0.63% [1] - The Northbound Stock Connect Index fell by 0.4% [1] - Total trading volume across the three markets reached 21,612 billion yuan, an increase of 36 billion yuan compared to the previous day [1] - Over 3,400 stocks declined across the three markets [1] Sector Performance - The humanoid robot, cinema line, AI agents, liquid cooling servers, oil and gas petrochemicals, digital currency, and semiconductor sectors saw the largest gains [1] - The mini-sized Jin Ying Gain Currency ETF experienced a notable increase of 5.01% [1] - The robotics sector surged in the afternoon, with several ETFs including Ping An Fund's Auto Parts ETF, Penghua's Robotics ETF, E Fund's Robotics ETF, and Invesco Great Wall's Robotics 50 ETF all rising over 4% [1] - The chemical sector also performed well, with E Fund's Chemical Industry ETF and Huaxia Fund's Petrochemical ETF rising by 2.57% and 2.45% respectively [1] - The non-ferrous sector saw an increase, with Wan Jia Fund's Industrial Non-Ferrous ETF rising by 2% [1] Declining Sectors - The Hang Seng Index's Hong Kong Stock Connect ETF continued to decline, dropping by 5.85% [1] - Gold prices fell, leading to declines in gold-related ETFs including the Gold Fund ETF, Shanghai Gold ETF, and Gold ETF, which all dropped by 2% [1] - The Hong Kong pharmaceutical sector continued to decline, with the Hong Kong Innovative Drug ETF falling by 1.55% [1]

Core Viewpoint - The investment accounts managed by the company have shown a mixed performance this year, with a total profit of 1.9 million yuan, down from a peak of 2.3 million yuan earlier in the year, indicating a drawdown of 400,000 yuan [2][3]. Group 1: Account Performance - The total assets in the on-market ETF account amount to 2.6 million yuan, while the off-market fund account holds 5.4 million yuan, and the advisory portfolio has 1.2 million yuan [7]. - The on-market ETF account has a year-to-date profit of 460,000 yuan, with a current yield of 40.19% [5][6]. - The off-market fund account has a year-to-date profit of 1.338 million yuan, with a yield of 34.21% [15][16]. Group 2: Investment Strategy - The company has shifted its strategy by reducing its position in a value ETF by 100,000 yuan and reallocating that amount to the Hang Seng Consumer ETF, which has seen a decrease in floating profit from 11% to 8% [4]. - The rationale for this shift includes the belief that consumer valuations are at historical lows and that there will likely be consumption stimulus policies next year, which could improve industry sentiment [5]. - The core holdings in the on-market ETF account focus on Hong Kong stocks, with significant investments in sectors such as innovative pharmaceuticals, technology, and consumer goods [8][9]. Group 3: Market Trends - The recent downturn in the Hong Kong stock market has not changed the company's long-term investment logic, which emphasizes the valuation advantages of Hong Kong stocks compared to A-shares [10]. - The company has noted that the recent performance of aerospace and satellite ETFs has been strong, contributing significantly to this week's profits [11]. - The company adheres to a philosophy of avoiding high-risk investments and focusing on undervalued sectors for long-term gains [12]. Group 4: Precious Metals Market - The precious metals market has experienced significant price increases, with platinum prices rising over 172% year-to-date, driven by demand from the aerospace sector [24]. - The company had previously identified platinum as a valuable investment but missed the opportunity to invest heavily at lower prices [21][24]. - The company advises against chasing prices in the current market, emphasizing the importance of strategic investment rather than following trends [25].

Market Performance - The Shanghai Composite Index rose by 0.53%, the Shenzhen Component Index increased by 0.88%, the ChiNext Index gained 0.77%, and the Northbound 50 Index was up by 0.39% [1] - The total market turnover was 1,897.2 billion yuan, a decrease of 24.1 billion yuan compared to the previous day [1] Sector Performance - The power and commercial aerospace sectors were active, while the precious metals and Hainan sectors experienced adjustments [1] - The commercial aerospace sector rebounded, with several ETFs such as the招商基金卫星产业ETF, 广发卫星ETF, 富国基金卫星ETF, and 永赢基金卫星ETF all rising over 5% [1] ETF Performance - In the ETF market, the mini-sized Hong Kong stock ETFs saw significant gains, with the国泰基金港股通50ETF hitting the daily limit, and the广发基金恒生ETF港股通 and 易方达基金港股通100ETF rising by 3.75% and 3.24% respectively, with latest premium/discount rates of 10.48%, 3.92%, and 4.32% [1] - The agricultural sector saw declines, with畜牧ETF, 农业ETF易方达, and 养殖ETF all dropping by 1% [1] - The Hong Kong innovative drug ETFs expanded their afternoon losses, with the 恒生生物科技ETF鹏华 down by 0.95% [1]

来源：新浪基金∞工作室 数据显示，12月23日，港股通创新药ETF工银(159217)遭净赎回2524.06万元，位居当日跨境ETF净流出 排名7/202。最新规模50.78亿元，前一日规模51亿元，当日资金净流出额占前一日规模的比例为 0.49%。 近5日，港股通创新药ETF工银(159217)遭净赎回2788.94万元，位居跨境ETF净流出排名第11/202。近10 日，港股通创新药ETF工银(159217)遭净赎回3058.09万元，位居跨境ETF净流出排名第14/202。近20 日，港股通创新药ETF工银(159217)遭净赎回5892.89万元，位居跨境ETF净流出排名第11/202。 港股通创新药ETF工银（159217）成立于2025年3月26日，基金全称为工银瑞信国证港股通创新药交易 型开放式指数证券投资基金，基金简称为港股通创新药ETF工银。该基金管理费率每年0.40%，托管费 率每年0.07%。港股通创新药ETF工银（159217）跟踪标的指数为港股通创新药（987018）。 规模方面，截止12月23日，港股通创新药ETF工银（159217）最新份额为38.25亿份，最新规模为50.78 ...

根据世界卫生组织预测，全球每年约有10亿例季节性流感病例，包括300万至500万例重症病例。在此 背景下，抗流感药物市场空间广阔。据头豹研究院预测，2024—2028年中国抗流感用药市场规模将以 20.2%的年复合增长率持续增长，到2028年有望达到269亿元。 （资料参考：21世纪经济报道《抗流 感药需求激增：市场"厮杀"升级，谁能抢占C位？》,2025.11.3) 今年，多款国产抗流感创新药密集获批上市，引发市场高度关注，2025年甚至被称为"国产流感创新 药元年"。有业内人士表示，国产流感创新药密集取得进展，是我国医药创新能力持续提升的必然结 果。这背后蕴藏着什么投资机遇？ （资料参考：证券日报《国产创新药破局 为应对流感提供"中国方 案"》，2025.11.12） 国产流感创新药商业化提速 2025年3月至7月，我国有三款抗流感创新药（玛舒拉沙韦片、昂拉地韦片、玛硒洛沙韦片）获批上 市，另有两款药物（玛氘诺沙韦、玛帕西沙韦）完成临床试验，已经提出了上市申请，预计不久将加 入市场竞争。专业人士分析称，目前国产创新药上市以后，销量在稳步提升，反映出这些产品在疗 效、安全性方面获得了认可。 （资料参考：央广 ...

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 1.91% on December 16, with a trading volume of 1.078 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of December 15, 2024, the fund's total shares reached 10.425 billion, with a total size of 8.174 billion yuan, reflecting a significant increase in shares and size compared to the previous year [1] Fund Performance - The fund manager, Ma Jun, has achieved a return of 64.28% since taking over management on January 3, 2024 [2] - The fund's performance benchmark is the National Index of Hong Kong Innovative Drugs, adjusted for valuation exchange rates [1] Holdings Overview - Major holdings in the fund include: - BeiGene (10.62% holding, market value 817 million yuan) - CanSino Biologics (10.55% holding, market value 812 million yuan) - Innovent Biologics (10.21% holding, market value 786 million yuan) - China National Pharmaceutical Group (9.62% holding, market value 741 million yuan) - CSPC Pharmaceutical Group (7.56% holding, market value 583 million yuan) [2]

流动性方面，截止12月15日，港股通创新药ETF工银（159217）近20个交易日累计成交金额108.35亿 元，日均成交金额5.42亿元； 港股通创新药ETF工银（159217）现任基金经理为刘伟琳、焦文龙。刘伟琳自2025年3月26日管理（或 拟管理）该基金，任职期内收益31.62%；焦文龙自2025年4月10日管理（或拟管理）该基金，任职期内 收益50.01%。 来源：新浪基金∞工作室 数据显示，12月15日，港股通创新药ETF工银(159217)遭净赎回133.43万元，位居当日跨境ETF净流出排 名15/200。最新规模50.62亿元，前一日规模53.04亿元，当日资金净流出额占前一日规模的比例为 0.03%。 近5日，港股通创新药ETF工银(159217)遭净赎回269.15万元，位居跨境ETF净流出排名第34/200。近10 日，港股通创新药ETF工银(159217)遭净赎回2672.71万元，位居跨境ETF净流出排名第11/200。近20 日，港股通创新药ETF工银(159217)获净申购1.02亿元，位居跨境ETF净流入排名第51/200。 港股通创新药ETF工银（159217）成立于202 ...

百亿市场待重构，替代空间广阔 今年，多款国产抗流感创新药密集获批上市，引发市场高度关注，2025年甚至被称为"国产流感创新药 元年"。有业内人士表示，国产流感创新药密集取得进展，是我国医药创新能力持续提升的必然结果。 这背后蕴藏着什么投资机遇？（资料参考：证券日报《国产创新药破局 为应对流感提供"中国方 案"》，2025.11.12） 国产流感创新药商业化提速 2025年3月至7月，我国有三款抗流感创新药（玛舒拉沙韦片、昂拉地韦片、玛硒洛沙韦片）获批上市， 另有两款药物（玛氘诺沙韦、玛帕西沙韦）完成临床试验，已经提出了上市申请，预计不久将加入市场 竞争。专业人士分析称，目前国产创新药上市以后，销量在稳步提升，反映出这些产品在疗效、安全性 方面获得了认可。（资料参考：央广网《全国整体进入流感流行季 多款国产流感创新药密集上市》， 2025.11.21；36氪《围剿"流感神药"奥司他韦，药厂卷起"一次治疗"新战场》，2025.11.14） 突破进口药局限，实现多重优化 国产新药与进口流感药玛巴洛沙韦作用机制相同，都是通过抑制流感病毒的CAP帽子结构依赖性内切 酶，从而阻断病毒复制。值得关注的是，这批国产新药并非简 ...

港股创新药概念股早盘走低，科伦博泰生物-B跌超7%，百济神州、三生制药跌超5%，康方生物、翰森 制药跌超4%。 受盘面影响，港股创新药相关ETF跌约2%。 | 代码 | 名称 | 现价 | | 涨跌 涨跌幅 ▲ | | --- | --- | --- | --- | --- | | 159297 | 港股通创新药ETF南方 | 0.837 | -0.019 | -2.22% | | 159570 | 港股通创新药ETF | 1.651 | -0.037 | -2.19% | | 159217 | 港股通创新药ETF工银 | 1.340 | -0.029 | -2.12% | | 159567 | 港股创新药ETF | 0.799 | -0.017 | -2.08% | | 159286 | 港股创新药ETF鹏华 | 0.855 | -0.016 | -1.84% | 有券商表示，从企业层面看，越来越多创新药企业从"研发投入期"进入"商业化兑现期"，核心产品销售 收入稳步增长，部分企业实现从减亏到盈利的跨越，为股价提供坚实支撑。同时，公募基金等机构对优 质标的配置比例提升，市场认可度持续提高。创新药行情的核心也 ...